News /
Palantir Stock Hits Record High Amid AI Hype, Iran Denial, and a No-Bid ICE Contract
Palantir's shares have reached an all-time high as the data analytics company faces scrutiny over a government contract and controversy around its CTO's comments on AI.
Palantir Technologies is trading at a record high, but the company is drawing attention for reasons that go well beyond its share price. A cluster of controversies - ranging from an unusual no-bid contract with U.S. Immigration and Customs Enforcement to its chief technology officer's remarks about AI researchers and cancer - has put the Denver-based data analytics firm in the spotlight.
What's Driving the Stock
Wall Street upgrades and strong retail investor enthusiasm have pushed Palantir's stock, traded on the NYSE under the ticker PLTR, to peak levels. The company has benefited from sustained interest in artificial intelligence infrastructure, particularly its work supplying data platforms to U.S. government agencies and large enterprises. Palantir has positioned itself as a key player in defence and intelligence data analysis since its founding in 2003, and renewed government spending on AI tools has kept investors optimistic.
The ICE Contract and Iran Denial
At the same time, Palantir is under scrutiny over a no-bid contract with ICE - meaning the deal was awarded without a competitive tender process - which has raised questions about government procurement practices and the company's expanding role in immigration enforcement.
Separately, Palantir has denied any involvement in a reported Israeli military strike on a school in Iran, pushing back against claims that its Maven AI system played a role. Maven is a U.S. military program that uses machine learning to analyze drone and surveillance footage. Palantir has been among the contractors associated with AI-assisted targeting tools, making the denial significant - and contested. The company has not provided detailed evidence to support its denial, and the claim remains disputed.
The CTO's Remarks on AI and Cancer
Adding an unusual dimension to the week's coverage, Palantir CTO Shyam Sankar reportedly said that some AI researchers have taken up smoking because they believe AI will eventually cure cancer before the habit kills them. The remark, cited in Business Insider, was apparently meant to illustrate the level of confidence - or recklessness, depending on your view - that has taken hold in parts of the AI research community.
Whether read as darkly humorous or genuinely alarming, the comment captures something real about the current mood in tech: a growing conviction that AI will solve problems so consequential and so soon that present-day risks can be discounted. That logic, applied to health, is hard to defend medically. Applied to investment decisions, it has driven billions of dollars into AI companies including Palantir itself.
Why This Matters Beyond the Stock Price
For Canadian readers, Palantir's trajectory is worth watching for a few reasons. Canadian pension funds and retail investors hold U.S. tech equities broadly, and Palantir's valuation - which has historically looked stretched relative to its revenue - reflects the same AI-driven enthusiasm affecting portfolios on both sides of the border.
More broadly, the questions swirling around Palantir touch on issues Canadians are grappling with domestically: how governments procure AI tools, what oversight exists when those tools are used in law enforcement or military operations, and how much trust the public should place in private companies handling sensitive government data. Canada has its own ongoing conversations about AI use in border services and public safety agencies, making the debate around Palantir's contracts a relevant reference point.
The company's ability to hit record stock levels while simultaneously denying involvement in a foreign military strike and defending a no-bid immigration contract says something about how markets are currently weighing controversy against growth potential in the AI sector. For now, investors appear to be betting on the growth.